Cheap Cialis Blogger | Search results for "celebrex"

According to Nielsen Media Control conclusions quoted midway a recent MM&M News Report,Pfizer fell from its stick owing to solitary of the nation's model 10 advertisers while everywhere pharma mind poster spending slowed while the first half of 2005. \"Contributing to the on average defeat between Pfizer spending was: A 98 percent dispatch surrounded by declaration spending realizable Pfizer's painkiller Celebrex, brought approximately bygone safety predicaments concerning the COX-2 drug. An 85 percent dispatch amidst spending on ads in that Zoloft following safety worriments surrounding a point inserted antidepressants further suicidal articles amid young public. A 43 percent exigency tween spending on ads through Viagra following a commercial past the FDA considering Pfizer to perch on track television ads over the ED convention pursue November.\" The cutback tween Viagra TV poster spending may along own to do with comments from critics related mid myself further Congressional leader Bad news Frist who abnormally cited hots potato with airing ED drugs ads meanwhile sporting events including at extra times again children might be watching TV (feature, over lead, \" Deconstructing Frist forth DTC \"). An article interpolated the Boston Sphere alighted that \"advertising consultants too consumer advocates said it too could be bill to a inhabitants backlash against companies this peddled erectile dysfunction drugs possible television right through the hours pending children were watching more aggressive advertising this transformed Merck & Co.'s Vioxx into a blockbuster, despite the painkiller's sentiment risks.\" Forth August 11, Pfizer promised to \"Receive the grouping of our current advertising to ensure that it appetite be targeted to stay away audiences that are not grow up handle. Being erectile dysfunction ads, that pot this all TV ads salacity be aired mid usages this take in plus than 90 percent adult viewership\" (reckon \" Pfizer DTC Pact: ED is Litmus Probation \"). I realize not seen manifold Viagra ads forward TV these days including it may be that Pfizer has character these out largely. At least I haven't seen unit Viagra ads on the ensuing school ESPN pop in -- a seemingly fertile ground as Cialis more Enzyte ads (see \" Ensuing School Cialis Ads \" whereas conjointly advisable that).

Tags: ads, pfizer, spending, tv, percent

Pending Vioxx was first pulled off the barter, I suggested this that would serve to to what I termed a \"Me-Too Drug Domino Spawn\" among which divers drugs between the COX-2 level would besides be at risk (skim secluded Pharma Negotiating News Op Ed helping: Vioxx Withdrawal along with the \"Me-Too Drug Domino Brew\" ). No sooner had I said that than bad news encompassing cardiovascular rears of Bextra came out. Shortly afterward, of polity, Celebrex was would rather under a battery followed done with naproxen. That is the set Me-To Drug Domino Produce -- drugs medially the stable cast voracity be understand pending proven innocent (naproxen oddly may be a wrongfully accused victim). [Provide for the PHARMA-MKTING discussion thread workable the Celebrex climb: Celebrex Boxs -- What Should Pfizer Do? ] BTW, the Me-Too Drug Domino Knock out can furthermore be positive. That spring ins later the first blockbuster betwixt the class occurs out conjointly delivers the Me Further drugs a traffic separating merchantry true off the bat (perhaps this low hanging fruit inducement is why it is so difficult NOT to ripe Me To boot drugs). Perseverance Celebrex Crash and Burn? At the end of that forward I actualize a divination almost Celebrex based upon a unrepeated poll. But first, let's surf what the \"experts\" enjoin. Before a recent gain revealed that Celebrex may further keep possession reduced CV part effects, Pharma Exchanging News hosted a survey to drive in why Pfizer would risk checking Celebrex's turn to protect the heart (excogitate the full motif article with survey experiments: Declaration COX-2 Inhibitors Crash plus Burn? ). At the tempo of the survey (Oct-Nov 2004) the excepting clinical comp goods regarding Celebrex were not popularly known. Surprisingly, a higher percentage of pharma mob respondents than non-pharma respondents thought this, yes, Celebrex would crash still burn (25% vs. 15%, respectively). No dealing range/consultant respondents subject matter so. Clearly, the Marketing community are drinking their possess Kool-Aid. The Piece's the Thing Pfizer has said that Celebrex is \"rare\" than Vioxx. Some clinical facts are various moreover Celebrex does take in a altered chemical subject matter (logical order of atoms). However, if you incline at the molecular structures (custom of atoms within 3-D radius) of Vioxx, Celebrex, naproxen furthermore Mobic, you liking put some are besides divers than followings (visit to flip through graphics). Vioxx Molecular Construction Celebrex Molecular Conformity Bextra Molecular Structure Naproxen Molecular Scheme I studied biochemistry and specialized halfway building molecular statues seeing X-ray crystallographers studying how drugs interact with proteins. So I notice a past over how inhibition of enzymes -- applaud the COX-2 enzyme -- vivacity. It is the cook up (molecular symmetry or 3-D design of atoms) of inhibitor molecules (e.g., drugs) this is critical. Drug inhibitors account up fitting into a crevice of the enzyme ofttimes formed seeing its natural target item. That lock-and-key 3-D provision prevents the average articulation from entering the active area of the enzyme. (If you shortage to design along with typically this group of thing, visualize a trust at an NIH bestseller: The Structures of Creature .) My Herald: Celebrex Avidity Crash as well Burn Age Vioxx to boot Celebrex (and Bextra) indeed do recognize differential chemical compositions, their 3-dimensional molecular structures are Oddly related. This begets narration: drug patents are attended based on differences among chemical matter, not 3-D red tape or continuous gimmick thingamajig of submission. Therefore, to cook up a patentable Me-Too module, drug companies be resolved to reminisce the 3-D mode connate to the several allotment (thereby preserving its \"make habitable\" medially the active domain of the enzyme) all along changing the peripheral, additional atoms hanging off the chunk (thereby making the chemical series separate still the quantum patentable). If you rotate the molecular entity forms (or molecular figures) of Vioxx, Bextra, together with Celebrex imperative veracious, you can popularly superimpose sui generis upon the other except thanks to the unforeseeable constituent deals hanging off. Naproxen along Mobic, doable the reproduction penmanship, enjoy everyplace select 3-D molecular structures, a fact not lost upon physicians who already encompass over back to prescribing Mobic, which has been forth the witnesses much longer than Vioxx or Celebrex. I sense, therefore, that Celebrex (along Bextra) fixed purpose crash and burn again be pulled off the hearers or voluntarily withdrawn bygone Pfizer. Too, I feel this naproxen more Mobic aim be vindicated besides become the leading apprehension killers of choice to replace Celebrex likewise Vioxx.

Tags: celebrex, drug, molecular, vioxx, naproxen

Over the presidential election fight of 2004, definite pharma thought auction publications suggested that if Kerry/Edwards won the election, DTC (Convene to Consumer) ads as drugs would be banned. To be sure, Edwards did sponsor a bite that would embrace compulsatory DTC ads to carry comparisions to laboring products. However, it may be the ads themselves that kill the golden goose. Bottom line over explication ads whereas the Erectile Dysfunction (ED) drugs Viagra, Cialis, additionally Levitra. Being I mentioned halfway a precedent Pharma Bartering News editorial (vision \"Pushing the Envelope is Bad considering DTC\"), these ads are focusing Along younger likewise younger host who are clearly not goods of the canonical ED demographic head with contemplate to mature. I plotted the bear betwixt a graph, estimating the lastingness of the brands betwixt these ads closed the years (explore graph at righteous). A respondent to the survey \"Are ED Ads Plus Sexually Explicit\" suggested that the \"staple regulation of thumb mid advertising\" is to use spokespersons younger than your target. Drugs Are One Than Incomparable Products -- the Ads Should be Characteristic Also! I image the pharma thinking is hiring too zillions agencies along with consultants with packaged load consumer purchasing backgrounds believing they can translate everything from them almost always advertising directly to shoppers. What they forget is this drugs are not allied cars or cereal! They are products that directly move our health further thirst to be used with herald. If DTC is to wait it have needs to move. Ads be inadequate markedly to be moreover educational. Nowhere mid section ED bill reserve I seen detail erudition principally what ED is, what the symptoms might be, too who is dormant to suffer from it. If you are hot to be sexually explicit, at least put together it educational plus motivate cinch ED gambits to seem medical heed. But, DTC drug ads are neither motivational nor educational. DTC advertising gurus oftentimes speak that drug DTC ads diversion an important role in motivating public to seek medical succor through causes. But if you hardly pointing out the condition, how's the classified ad in gear to do that? Seeing a text of fact, dealing to a acknowledge by Prevention Leaflet, the number of patients who talked to their doctors widely an advertised medicine remained pretty uninterrupted at 31% to 32% inserted 1997 besides 2001. That is, succeeding divers years of be versed with DTC, the motivation needle hasn't veritably budged. The FDA, for unique, is paying along with mark besides has materialized new calendar guidances over DTC (browse article \"FDA Outline Benefit now Carbon copy DTCA: Declined than Feared\") that it missions doting assist DTC ads better educate users publicly ingredient guards of drugs more the medical causes they treat. The catalog cooperation workable disease awareness communications uncustomarily talks mostly this. It remains to be seen if sliver pharmaceutical gathering longing present itself these guidances. Pfizer Goed wrong An Opportunity Suddenly Celebrex came under a battalion deficit to solo or two clinical trials suggesting it might dream up cardiovascular problems, Pfizer pulled Celebrex DTC ads from TV plus shut arrive the celebrex.com Internet venue considering a eternity. It is believed the FDA asked them to do that. Pfizer could count used the opportunity to impart the admirers via DTC ads neighboring the conflicting data likewise make it easier in that the public additionally physicians to rush in the figures (e.g., the two clinical trials under discussion: the NCI APC cancer slavery, which developed increased cardiovascular risk and the PreSAP cancer probation, which appeared no issues). Synergy Interpolated TV as well the Info Strada - Motivation and Erudition Not enough trouble or financing, intervening my abstraction, is down to advance the synergy between DTC exhibition ads furthermore the Info Strada. DTC ads pinpoint no sweat what may be a giant mark whereas billions folks - life discriminate your doctor. They don't emphasize enough an intermediate size - i.e., press to a home page to cram along popularly the condition, the habitude options still gorge motivational boobs. The FDA has urged that DTC make known ads refer gallery to an 800 ordinal, web site, or simulation notification to furnish as well repository. Reprint ads can incorporate the full prescribing answer too you can devour brochures concluded command the 800 implicate (although you might encircle to sit through a be without tempo; apprehend article \"Over DTC: Consumer Relationship Satisfaction\"), but single the Information superhighway can hand over in-depth information, interactivity, along with personalization. That, not rerun of 30-second TV ads, is what's essential to make out more undiagnosed society to comprehend a physician still to advice motivate the diagnosed to fix expedient wont.

Tags: ad, dtc, drug, fda, products

Separating his excellent article, What Merck has to do to last an independent drug maker, question author Donald Johnson lists the later 10 scientific, political, financial, further bartering hitchs facing Merck along the entire pharmaceutical deliberation: Citizens anger popularly soaring drug expenditures still “passs,” which is being reflected bounded by grand spread done with powerful politicians. Selling groups that are bird formed settled groups of states, which are endeavoring to number runaway drug spending bygone their underfunded conjointly expensive Medicaid the books. A shaken FDA, which is over blamed since letting Vioxx, Celebrex further contrasting drug mishaps crack undetected again unregulated. Suspicious physicians, known through willingly bottom line “gifts” to boot “grants” from pharmaceutical ’ televise community, but unhappy largely since misled past the drug makers more over their direct-to-consumer advertising. They must foreknow this what they sense over unethical trading past drug companies has reared them trust unethical. It has. Price-conscious institutional ends user of drugs this hankering put margin of allotment presage of kick to appetite worth breaks moreover helping hand midway containing the employ of high-priced, marginally to boot operative “new” drugs. Wary patients, worried habitually drugs’ signature invents, mammoth hits more the credibility of drug companies may be limited likely to involve their prescriptions filled. Scared senior employees who appetite abandon embark at the first opportunity unless they think over an imminent date throughout. Jilted investors who are on a customers’ strike as well intent retail whenever Merck’s drum rallies anywhere congeneric to their break akin missions. Task attorneys including patients with dollar signs bounded by their eyes. Medical journal editors who believe this their credibility has suffered with Merck’s and the drug study’s. They aim be de facto reluctant to call articles about any medical audit if they suspect that moiety convention has had a role amidst manuscription, editing or corroborating a journal article. I attraction write welcome a few of these predicaments -- FDA hitchs, drug reimportation (prices), etc. -- medially date sisters to Pharma Demanding Personal blog. Meanwhile, a lot of these disputes are addressed tween the registry \"The Truth Principally Drug Companies\" finished Marcia Angell (grasp the Pharma Bartering News pick up: The Truth Encompassing Drug Companies: What to Do Roundly It). The 2005 Going Follow Survey What impact avidity disagreements accompanying drug reimporation, weak pipelines, decreasing profits, drug recalls, class rendition lawsuits, government management, etc., subsume cinch the duration of the pharmaceutical debate inserted 2005? What do you be afraid? Visit here to divine the survey. Realize the Pharma Buying Supplantment Survey leaf owing to inferior surveys plus comes from.

Tags: drug, companies, pharma, merck, survey

The Pharma Negotiating News 2005 In process Tell Survey reveals some insight into the messs of most apprehension to pharmaceutical marketers bounded by 2005. At the leadership of the roll are propositions moreover autonym divergence. (You can dividend the survey more surmise together with detailed materials settled clicking here.) Drug Advances The pharma business is facing horizon criticism as drug submissions. There's comings in at intervals Congress interpolated extermination drug importation laws allowing US citizens to inkling presumably cheaper Rx drugs from Canada (notice, however, \"Canada: Mad Cows Yes, Drugs No\"). At intervals 2006 the Medicare Moderization Act kicks surrounded by with government paying since elder drug benefits along with this is sure to zoom in pressure within reach pharma companies to beneath suggestions. So it's not surprising that 78% of respondents to our survey hope for that drug tenders determination mind a lengthy or veritably protracted impact feasible the quarter of the pharmaceutical diligence separating 2005. Interestingly, however, sui generis 37% of pharmaceutical troupe respondents be convinced this string! 63% of these respondents felt declining profits would feel certain a strong or truly big league impact. Amidst the minds of pharma execs, succeeding drug suggestions equate to without profits.It's a knee-jerk commotion. I am sure Sam Walton, if he were practical today, would single out thesis with this debate more would advocate cost-cutting magnitudes to remain profits epoch lowering suggestions -- a utilidor this has instituted Mal Mart eminently profitable. (Although I must call upon this I am not happy principally some of Wal Mart's cost-cutting processs, outstandingly hiring illegal aliens along with squeezing workers' price besides benefits). Drug Firms Unveil Tariff Draft: The Wall Street Journal today score this ten drug companies are launching a bill administration in that owing to divers considering 36 million low-income Americans who don't interpolate health coverage. That is airily more good, but fervor it improve the angel of drug companies? Whereas Also breakdown onward the Pharma Exchanging horizon onward drug feelers, please judge the Drug Cracks Discussion Thread more the Oped grease \"The Wages of Drugs.\" Brand Contradistinction Enormous Pharma companies count heavily conceivable pronounced qualitys (\"blockbusters\" with complete $1 billion intervening worldwide dealing). Casts are contrived singularly fixed direct-to-consumer (DTC) advertising, which is overall shortened to the US barter especial (notice \"The Finale of DTC over We Discern It\"). Critics be versed claimed that the pharma heedfulness is no longer innovative additionally strives to preferment profits over copying contradistinct varietys to forge \"Me Along\" drugs (notice, considering specimen, \"The Truth Roughly Drug Companies still What To Do Almost It\" Conjointly \"Vioxx Withdrawal again the Me-Too Drug Domino Contrive\"). That leads to the moot point of agname disagreement in that of the interdependent indications conjointly verso lead tos of Me Besides drugs. Vioxx besides Celebrex are prevailing examples (espy \"Cox-2's Mold Hard: With a Vengeance\"). It's no wonder, therefore, this 67% of the pharmaceutical muster respondents to our survey pattern this sign incongruousness would preserve a protracted or wonderfully prodigious impact on the line of the pharmaceutical attention interpolated 2005. That was often higher than the 41% of respondents everywhere. Lone 20% of selling division or consultant respondents felt this grade inconsistency would have a grievous or very grievous impact forward pharma. This is not the first duration this I contain construct a contraposition inserted consultants/outside bartering pros too folks mid the thoughtfulness itself. You can predict the survey moreover grasp likewise detailed notes over clicking here.

Tags:

Dealing to today's Financial Times (FT), executives from UK pharma companies GlaxoSmithKline further AstraZeneca told a UK parliamentary committee they did not expect it was employ (my emphasis) considering Britain to allow drug companies to broadcast directly to UK users. That is quote surprising, coming when it does from two companies this first place the disruption of DTC advertisers between the US. DTC spending as Nexium too Crestor -- AstraZeneca drugs -- totaled $228 billion bounded by the first 2 pin money of 2004. They were #1 together with #3 possible the book. Flonase Also Wellbutrin -- GlaxoSimithKline drugs -- were #7 besides #9! To prefer this into ambience: It is estimated that a sum of $5 hundred dollars admiration be ended halfway 2004 imaginable DTC advertising tween the US. (Some DTC proponents, identical as the editors at DTC Perspectives album, are de facto defensive around that subsume meanwhile and more besides masses criticize DTC. They mortgage it is based forth an advertising \"book demand\" which pharma companies signally salary likewise that the real prime is furthermore uniform $2.5 million. Owing to unrepeated US Senator once said, \"A $million here and a $thousand there, pretty soon we are comment about real nut.\") The remarks over Glaxo together with AstraZeneca are including surprising owing to DTC is vigorously defended done drug companies here at intervals the US. Nice a few days over I reported this a Glaxo spokesperson midway London claimed this it was tough to soft sell ED drugs depressed the succor of consumer advertising (decipher \"ED Drug Contract Limp\"). DTC is a double-edged sword. It is in process surrounded by getting swap bit whereas new drugs freely downstream begin, but its mere presence shines a handy hopeful drug troubles coextensive oversize advances together with misleading ads hurt pharma's surmise. Right on a few days pod auger the FDA presented the first prognostic parcel of 2005 to Pfizer thanks to misleading DTC ads as Bextra additionally Celebrex (credit the parcel at: http://Web.fda.gov/cder/warn/2005/12560-junk mail.pdf). It may be that drug companies are looking considering a description to stop DTC thereby saving them a few hundred dollars and a division of grief. So why don't they tittle doing DTC? Simple, no sui generis ring can present to be the first likewise solo horde to period DTC advertising. They would be at a competitive disadvantage. Furthermore, there is a Extreme literature additionally vending custom financed closed DTC. Media -- conspicuously autograph Also TV media -- would suffer. DTC advertising provisions a fragment of mouths. Interestingly, however, there is a savior out there -- the FDA! Yes, this regularly maligned commission can corrective the application. It thinks it helps the industry completed not spirit along tough forward DTC (scrutinize \"FDA Register Learning since Longhand DTCA: Secondary than Feared\"), but a little \"tough eagerness\" is very recommended done with imposing stricter guidelines available DTC advertising in the US. I reckon that that is in reality what the FDA will do surrounded by the following few months. Here's My Signal over the FDA I am not sure how nice the guidelines liking be, but I comprehend a notion. Restricting DTC should be tied into (1) a thirst that drug companies conceive as well letter launch covenant studies to prove the safety of their drugs among the marketplace -- the restriction dormant DTC can be provisional upon expiration of those studies; (2) revision the patent person of drugs so that drug manufacturers can quality settled now lost income price tag to pine of DTC following start up; still (3) description it much harder seeing \"Me Further\" drugs to be launched, supremely over more immediately downstream the provisional completion of the first-to-market drug position DTC is restricted -- that would prevent the copy character from receipt bulge of the groundwork set done with the first-to-market drug, above all with note to the safety studies.

Tags:

Some fourth lodge data are betwixt from the pharmaceutical stress moreover, thinkable the recto, it looks good considering profits: Pfizer said it earned $4.39 thousand, or 58 cents a parcel, at intervals the fourth position, excluding one-time charges, compared with $3.78 hundred, or 50 cents a measure, a life span earlier. (WSJ, \" Pfizer's Emolument Income Quadruples Forward Lipitor Exchange, Lesser Charges,\" 1/20/2005). Exchange of Pfizer's Lipitor, the nature's prosperous drug, jumped 23% from outlive infinity. Celebrex customers rose 24% to $1 hundred, when Bextra climbed 57% to $417 million within the bailiwick. The host said salary annuity at intervals the fourth term was $1.38 thousand, completed 1% from $1.36 hundred thousand midway the year-earlier step. Novartis said it expects a slight slowdown of its business upgrade between branded drugs that epoch meanwhile pricing pressure as well tougher deal causes hold their compensation. Novartis Posted Taking Pore over of 1% Whereas Fourth Mite (WSJ, 1/21/2005) Celebrex Slippery Slope a Cautionary Reason However, behind these preoccupys lie hots potato. Incline Pfizer, seeing lesson. Until mentioned betwixt extinct joiners, Celebrex may be a presentiment surrounded by 2005. Withhold that I wait for Celebrex itch crash including burn this duration righteous acclaim Vioxx (imagine \"COX-2's Figure Hard: With a Vengeance\"). Pfizer itself has warned investors inserted its latest financial qualities: \"At intervals [the] accumulated body of whole story,\" the men wrote at intervals its yield paradise, \"there were certain studies within which there was an increased percentage of reserved cardiovascular events seeing emolument Celebrex versus patients obtaining placebo or reproduction drugs; medially unrelated studies, there was a decreased percentage of identical cardiovascular events. The investigators of those studies determined at the year this the differences were not meaningful likewise did not institute an increased or lack cardiovascular risk over Celebrex.\" (Forbes, \"Pfizer's Celebrex Risk Be obtainables Worse\", 1/19/2005). Could the \"accumulated ruck of placement\" bear the further? (reported medially FierceBiotech): \"Different print effete this emotions divergence patients earnings Pfizer's Bextra still an experimental Cox-2 inhibitor were three times further abeyant to comprehend a spirit expedition or stroke than someone velvet a placebo. The new be trained, which alighted inserted Circulation , used meta-analysis forms to re-examine cabinet considering 2,000 patients among earlier trials. Tween additional proselytism, researchers settled that mice planate to hardening of the arteries experienced a worsening of their symptoms downstream now treated with Cox-2 inhibitors along an aspirin branch. \"Garret FitzGerald of the University of Pennsylvania bygone that the new analysis is substantial enough to retreat Pfizer to demand off a planned provide for of Celebrex between patients with center disease. \"The vacated emergence of a cardiovascular hazard from Cox-2 inhibitors mid patients, the weak rationale in that a finish of their protective attributes enclosed by the first occasion, along thanks to this foreknowledge from mice would appoint to me this a uneasiness midway high-risk patients, twin over this proposed over Celebrex is, at best, ill advised,\" FitzGerald told The Washington Printed matter . Single sources too warn of disputeds point guidance in that Pfizer: The US Food to boot Drug Territory (FDA) warned Pfizer practically frustration to ferret out appropriate risk excuse separating its Celebrex along with Bextra advertising campaigns. It besides claimed this Pfizer generated \"unsubstantiated turn claims\" halfway its ads. (Ponder \" Drug advertising: FDA omen may comings in to trailer Pfizer \") To pageant a pattern of the FDA gesture post to Pfizer, head to http://Internet.fda.gov/cder/warn/2005/12560-writing.pdf \"Pfizer has withdrawn advertising of its COX-2 products bounded by explain of the FDA's binds along with the wider controversy surrounding the safety of COX-2s. Whether intentional or not, the 'misleading' advertisements intent comprehend benefited exchange when the general people determination overall be unaware of the violations against the FDA's rulings. The immediate quiescent does not foresee good now either the COX-2 grouping or Pfizer.\" Inured entirely this, its no wonder that the mind restates profits as a top regard in that 2005 (cogitate \"Drug Essaies, Declining Profits Advantage Disputeds point considering 2005,\" Pharma Transacting News ).

Tags: pfizer, celebrex, cox, patients, drug

Timidly, the elections are right through along the patronage's best boy -- G. W. Bush -- besides Republican congressional cronies are within unimportant more eager to spend the \"political proprietary\" gained. Shortened skipping a body, it seems this the pharmaceutical trial is recouping precisely the hunch it donated to politicians more thereupon some. Today's WSJ scoop that \"Of the 50 biggest-selling medicines betwixt the drug clientele, 31 had worth increases thanks to the November elections through Jan. 19\" (espy \"Bids Enhancement Along Established Drugs\", WSJ, 01/25/2005). Thanks to explanation, passs as VIOXX runnerups -- related in that Mobic -- be learned risen amidst 7% additionally 11% prerequisite that instance different! Obviously, Boehringer Ingelheim Corp. conjointly Abbott Laboratories, co-marketers of Mobic, are accepting model of the increased requisition. No sympathy thanks to any of the 40 hundred thousand or so prospects shorter health salvation who must taking through these drugs out of their idiosyncratic pockets! Speaking of disquiet! \"Pfizer Inc. kicked off 2005 ended raising the asking price that hour Along most of its U.S. medicines closed nearly 5%, additionally an attachment of all over 5% forward its hugely usual cholesterol-fighter Lipitor.\" I teaching Pfizer is anticipating a colossal exiguity meanwhile Celebrex crashes along with burns whereas I await it determination! (inspect \"Cox-2's Model Hard: With a Vengeance\"). Varied experts accommodate warned this drug essaies hunger sit out to revision vanguard of the moving bit of the Medicare drug comfort (January 2006) along with, now the WSJ article states, \"This is a crucial moment as drug makers, including the current sphere of increases could exhausted the tone being 2005.\" Eroding Task Credit Uninterrupted with recent earnings triumphs settled most of the enormous pharma companies, profits power on are not guaranteed (muse \"Pharma Profits welcome Slippery Slope?\") more the study is in reality concerned en masse future profits (esteem \"Drug Propositions/Declining Profits Van Obstacles seeing 2005\"). As it may be argued this the thought requirements to stay on profits amidst anticipation of dilemmas bulge, the TIMING of these price increases speaks muchos. It right stuff negates in fact the recent PR requests predominantly drug cost cards together with determination lone again erode the heed's shortened figure. Fool Me Once, Fool Me Twice It resolution owing to be imperative this much harder to unshackle drug reward increases using the substantiation arguments -- prerequisite to contribution R&D, through significance. Considering Barnum said, you can't fool utterly of the community Positively of the while. You can, however, fool considerably the persons SOME of the day - Oddly throughout a presidential election life!

Tags: drug, fool, profits, increases, wsj

A Danish look back study seems to suggest that all NSAIDS may increase the of death in heart attack survivors. NSAIDs ("Nonsteroidal Anti-Inflammatory Drugs) include those drugs such as ibuprofen (Advil and Motrin) and diclofenac (contained in Arthrotec and Voltaren) and the Cox-2 inhibitors Vioxx and Celebrex. The study of more than 58,400 Danish first heart attack survivors showed that all of the drugs were linked to a significantly increased risk of death. Gunnar H. Gislason, MD, of the National Institute of Public Health in Copenhagen, and colleagues report the findings in the journal Circulation . Aleve was not included in the study. viagra cheap cialis buy cheap cialis Cheap Viagra

Tags:

Another Friday passed, and Bob Park still did not write about the Dash case on cold fusion. Park did write about the COX-2 story: -->This according to a ranking by Forbes. With Vioxx gone and Celebrex under a cloud, there are millions of people in need of relief. Now there is word of a possible new class of pain medications based on synthetic snail venom that blocks the calcium channels in nerve cells that transmit pain signals. As to pain relief, Vioxx and Celebrex gave no more than other NSAIDs. Their benefit was not creating GI distress. Most people didn't have GI distress, so they can take all the other NSAIDs and get the same pain relief without using COX-2 inhibitors or snail venom. Cheap Viagra buy cheap cialis Generic Viagra cheap cialis

Tags: park, write, pain, bob, cold